Twist Bioscience Adds Respiratory Virus Panel to Infectious Disease Product Line
June 30 2020 - 7:00AM
Business Wire
-- Panel Includes Adenoviruses,
Coronaviruses, Influenzas, Rhinoviruses and More --
Twist Bioscience Corporation (Nasdaq: TWST), a company enabling
customers to succeed through its offering of high-quality synthetic
DNA using its silicon platform, today announced the availability of
the Twist Respiratory Virus Research Panel, a robust
next-generation sequencing (NGS) approach to detecting a wide range
of respiratory diseases including SARS-CoV-2, several other
coronaviruses, influenzas, rhinoviruses and respiratory syncytial
virus. The panel will be bundled with an analysis platform from One
Codex to enable an easy-to-use, complete end-to-end workflow that
begins from the Twist target enrichment panel and continues through
publication-ready visualizations.
Detecting and identifying viral pathogens remains an acute
global health concern, exacerbated by the COVID-19 global pandemic.
A wide range of viral pathogens manifest similar symptoms making it
difficult to identify the cause(s) of disease. Unlike common RT-PCR
assays, which detects only one pathogen at a time, the Twist
Respiratory Virus Research Panel is designed to identify, detect
and characterize active pathogen presence, screening for 29 common
human respiratory viruses in one sample.
“The symptoms of COVID-19 are extremely varied, in many cases
mimicking a number of other common illnesses including influenza,
adenovirus infections or even the common cold,” said Emily M.
Leproust, Ph.D., CEO and co-founder of Twist Bioscience. “By
offering a comprehensive respiratory panel with the ability to
detect and characterize a wide range of viruses, this assay
provides an important tool that fits within multiple workflows to
appropriately identify and research the underlying virus causing
the infection or co-infection. Importantly, this panel can also be
used to surveil populations for early signs of outbreak, viral
transmission and evolution to enhance public health response.”
About the Twist Respiratory Virus Research Panel
The Twist Respiratory Virus Research Panel targets all common
viral pathogens that cause respiratory symptoms in humans. The
panel includes both RNA-based and DNA-based viruses in one kit with
41,047 nucleic acid probes. The probes are subject to Twist’s
proprietary NGS quality control process, ensuring the probe
representation in every lot meets our specifications to provide
researchers with high quality, highly uniform capture
performance.
The panel allows researchers to separate COVID-19 symptoms from
those of other respiratory illnesses, both influenza- and
non-influenza-related. The probes within the panel cover both viral
genomes and their reverse complements. The panel is optimized for
standard and FastHyb or Fast Hybridization workflows, resulting in
extreme uniformity after capture with FOLD 80 base penalty in the
range of 1.2 to 1.5 for the synthetic viral targets. Highly
sensitive, the panel is able to detect as little as 100 copies of
viral material, and has coverage of > 99.9% of the genome at 1X
or greater post-enrichment. All viruses included can be found here.
To order the panel, visit:
https://www.twistbioscience.com/coronavirus-research-tools?tab=new-products.
An End-to-End Offering that Includes Analysis with One Codex
Platform
The Twist Respiratory Virus Research Panel includes genetic
analysis on the One Codex platform allowing customers to generate
easy-to-share publication-ready visuals and reports for clinical
research for a complete solution from panel to results. One Codex
is the leading bioinformatics platform for microbial genomics,
supporting taxonomic and functional analysis of next-generation
sequencing (NGS) data.
The Twist Respiratory Virus Research Panel is available for
Research Use Only (RUO).
Customers purchasing the Twist Respiratory Virus Research Panel
are subject to Twist’s leading biosecurity screening protocols and
applicable laws and regulations.
About Twist Bioscience Corporation
Twist Bioscience is a leading and rapidly growing synthetic
biology and genomics company that has developed a disruptive DNA
synthesis platform to industrialize the engineering of biology. The
core of the platform is a proprietary technology that pioneers a
new method of manufacturing synthetic DNA by “writing” DNA on a
silicon chip. Twist is leveraging its unique technology to
manufacture a broad range of synthetic DNA-based products,
including synthetic genes, tools for next-generation sequencing
(NGS) preparation, and antibody libraries for drug discovery and
development. Twist is also pursuing longer-term opportunities in
digital data storage in DNA and biologics drug discovery. Twist
makes products for use across many industries including healthcare,
industrial chemicals, agriculture and academic research.
Follow us on Twitter | Facebook | LinkedIn | YouTube
Legal Notice Regarding Forward-Looking Statements
This press release contains forward-looking statements. All
statements other than statements of historical facts contained
herein, including without limitation Twist’s ability to deliver its
respiratory virus panel to its customers, are forward-looking
statements reflecting the current beliefs and expectations of
management made pursuant to the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995. Such
forward-looking statements involve known and unknown risks,
uncertainties, and other important factors that may cause Twist
Bioscience’s actual results, performance, or achievements to be
materially different from any future results, performance, or
achievements expressed or implied by the forward-looking
statements. Such risks and uncertainties include, among others, the
risks and uncertainties of the ability to attract new customers and
retain and grow sales from existing customers; risks and
uncertainties of rapidly changing technologies and extensive
competition in synthetic biology could make the products Twist
Bioscience is developing obsolete or non-competitive; uncertainties
of the retention of a significant customer; risks of third party
claims alleging infringement of patents and proprietary rights or
seeking to invalidate Twist Bioscience’s patents or proprietary
rights; and the risk that Twist Bioscience’s proprietary rights may
be insufficient to protect its technologies. For a further
description of the risks and uncertainties that could cause actual
results to differ from those expressed in these forward-looking
statements, as well as risks relating to Twist Bioscience’s
business in general, see Twist Bioscience’s risk factors set forth
in Twist Bioscience’s Quarterly Report on Form 10-Q dated May 12,
2020. Any forward-looking statements contained in this press
release speak only as of the date hereof, and Twist Bioscience
specifically disclaims any obligation to update any forward-looking
statement, whether as a result of new information, future events or
otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200630005326/en/
Investor Contact: Argot Partners Maeve Conneighton 212-600-1902
maeve@argotpartners.com
Media Contact: Angela Bitting 925- 202-6211
media@twistbioscience.com
Twist Bioscience (NASDAQ:TWST)
Historical Stock Chart
From Jun 2024 to Jul 2024
Twist Bioscience (NASDAQ:TWST)
Historical Stock Chart
From Jul 2023 to Jul 2024